NCT03186040View on ClinicalTrials.gov

Open-label Clinical Trial of Lacosamide in ALS

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

July 13, 2017

Primary Completion Date

April 30, 2020

Study Completion Date

May 31, 2020

Conditions
Amyotrophic Lateral Sclerosis
Interventions
DRUG

Lacosamide

Sodium channel blocker

Trial Locations (1)

260-8677

Chiba University Hospital, Chiba

All Listed Sponsors
lead

Chiba University

OTHER

NCT03186040 - Open-label Clinical Trial of Lacosamide in ALS | Biotech Hunter | Biotech Hunter